Analysis:

Performance of Acutus Medical Inc. during the period:

Acutus Medical Inc. is an arrhythmia management company that is focused on improving the diagnosis and treatment of cardiac arrhythmias. The company’s primary product is the AcQMap imaging and mapping system which offers a unique and unmatched approach to mapping drivers and maintainers of arrhythmia with fast speed and accuracy. Acutus Medical Inc. is committed to advancing the field of electrophysiology with an innovative array of products and technologies. The company’s portfolio includes novel access sheaths, diagnostic and mapping catheters, conventional and contact force ablation catheters, and imaging, mapping, and software consoles.

Acutus Medical has achieved significant milestones, including the launch of its commercial-grade console and software products in the first quarter of 2020. Additionally, the company has established the ongoing development and expansion of its Bi-Lateral Distribution Agreement with Biotronik, received 510(k) clearance and CE Mark for its second-generation AcQMap console and SuperMap software suite, and completed the U.S. clinical study for the AcQBlate Force sensing ablation catheter and system. These milestones have been critical to the company's launch and future market adoption, as they have helped to validate its value proposition and optimize workflow.

As of March 31, 2023, Acutus Medical Inc. had generated revenue of $4.2 million, an increase of 12.8% over the same period in the previous year. Of this revenue, 46% was from customers located outside of the United States. The company has reported a net loss of $16.3 million for the three months ended March 31, 2023, a significant improvement over the net loss of $40.0 million for the same period in the previous year. Acutus Medical Inc. has an accumulated deficit of $534.6 million as of March 31, 2023, and working capital of $84.7 million.

Competitive position, current trends, and other relevant factors that could impact Acutus Medical Inc.'s future performance:

Acutus Medical's unique and unmatched approach to mapping drivers and maintainers of arrhythmia has given it a competitive advantage in the market. The company's product portfolio is unique and highly differentiated, providing a complete solution for the catheter-based treatment of cardiac arrhythmias in each of its geographic markets. The increasing global prevalence of arrhythmia, coupled with the economic and clinical challenges associated with arrhythmia treatment, provides a strong growth opportunity for Acutus Medical Inc.

Additionally, the ongoing development and expansion of its Bi-Lateral Distribution Agreement with Biotronik, as well as the recent sale of its left-heart access portfolio to Medtronic, further strengthen the company's competitive position. These transactions demonstrate the market's confidence in Acutus Medical's innovative products and technologies.

As the company continues to expand its sales presence globally, it is likely to face challenges related to market competition, regulatory approvals, and clinical trial milestones. However, Acutus Medical Inc. has a proven track record of achieving significant milestones, and its ongoing partnerships and collaborations with leading companies in the field are expected to drive continued growth and success.

Forward-looking analysis:

Moving forward, Acutus Medical Inc. is expected to continue its growth trajectory as it focuses on expanding its global sales presence and portfolio of innovative products and technologies. The company is expected to leverage the geographically concentrated nature of procedure volumes and the recurring nature of its sales to drive an increasingly efficient commercial model.

Additionally, Acutus Medical Inc. is expected to expand its product line and clinical offerings, as well as focus on new product development, acquisitions, and global partnerships to enhance its competitive position in the market. The company's ongoing efforts to expand its sales presence globally, coupled with its unique and highly differentiated product portfolio, provide significant growth opportunities for the future.

In conclusion, Acutus Medical Inc. has made significant progress in advancing the field of electrophysiology with its unique and innovative product portfolio. As the company continues to expand its global sales presence and product line, it is likely to see continued growth and success in the coming years.

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Acutus Medical Inc

Acutus Medical (AFIB) sees revenue growth of 12.8% in Q1 2023.

Acutus Medical, a leading arrhythmia management company, has recently reported its financial results for the first quarter of 2023. The report demonstrated strong year-over-year improvements in non-GAAP gross margin, operating expenses, and cash burn. The company's revenue for the first quarter of 2023 was $22.4 million, which is a significant increase from $13.7 million for the same quarter in the prior year, primarily due to a higher production volume, lower manufacturing variances, and a reduced manufacturing overhead structure.

Acutus Medical's net loss for the first quarter of 2023 was $16.0 million, or $0.57 per share, compared to a net loss of $28.1 million, or $1.00 per share, for the same quarter in the prior year. This improvement resulted from the company's restructuring actions in the first half of 2022, reduced discretionary spend, and reprioritization of certain research and development programs.

The company's financial position remains strong, with cash and cash equivalents of $76.7 million as of March 31, 2023. Acutus Medical uses non-GAAP financial measures to assess its overall performance, which may not be comparable to other companies or appropriate measures for comparing the performance of other companies against Acutus.

Overall, Acutus Medical's financial report for the first quarter of 2023 demonstrated strong year-over-year improvements in financial performance, including revenue and net loss, which should be attractive to investors looking for growth opportunities in the arrhythmia management industry.

Form 8-K - Current report - Item 2.02 Item 9.01

$AFIB Reports Strong Q1 2023 Results with Improved Gross Margin, Reduced Operating Expenses, and Increased Revenue

Announcement: AFIB 8-K Special Filing

Performance Analysis:

Acutus Medical, Inc. is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company has a broad portfolio of highly differentiated electrophysiology products that include diagnostic and mapping catheters, ablation catheters, mapping and imaging consoles, and accessories. The company's foundational and highly differentiated product is the AcQMap imaging and mapping system, which offers a novel approach to mapping the drivers and maintainers of arrhythmias with unmatched speed and precision. The company has established a direct selling presence in the United States and select markets in Western Europe where cardiac ablation is a standard of care and third-party reimbursement is well-established. In other international markets, the company leverages its partnership with Biotronik to install its AcQMap console and workstation with customer accounts and then to sell its disposable products to those accounts. 

In 2022, the company generated revenue of $16.4 million, of which 47% was from customers located outside of the United States. However, the company has been generating significant losses since its inception. The net loss for the year ended December 31, 2022, was $39.6 million, and the accumulated deficit was $518.3 million. 

Forward-looking Analysis:

The company's sales organization will continue to focus on driving utilization and procedure growth in targeted geographic regions. The company intends to prioritize maximizing console utilization and procedure volume growth in targeted geographic regions, as well as have a more focused scope of product development initiatives. The company is also committed to ongoing development and expansion of its Bi-Lateral Distribution Agreements with Biotronik, FDA 510(k) clearance and CE Mark of its second-generation AcQMap console and SuperMap software suite, and the completion of enrollment in its US clinical study for the AcQBlate Force Sensing Ablation catheter and system. 

However, the company expects to continue to incur net losses and negative cash flows from operations for at least the next couple of years due to increased costs for employee-related expenses, director and officer insurance premiums, audit and legal fees, investor relations fees, fees to members of its Board of Directors, and expenses for compliance with public company reporting requirements. 

Partnerships with companies like Biotronik and Medtronic may provide opportunities for Acutus Medical to expand its reach and product offerings. However, competition within the electrophysiology market remains a challenge. The company may also face regulatory and clinical trial hurdles that could affect product development initiatives and timelines. 

In a quote from the CEO, Vince Burgess, “As we enter our next strategic phase of growth, I’m excited to see the team’s execution and momentum continue to drive our commercial adoption while broadening our product portfolio to address the full range of unmet clinical needs in cardiac arrhythmia. With important milestones achieved for both the AcQMap and its force sensing ablation catheter, and our expanding global distribution capable of targeting high volume EP programs, we are poised for tremendous growth in the years ahead.” 

Overall, Acutus Medical's innovative products and strategic partnerships provide a strong foundation for future growth. However, ongoing net losses and competition within the electrophysiology market remain concerns that investors should consider when assessing the company's potential performance.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Acutus Medical, Inc.: Expanding its Global Reach and Products Portfolio to Address Unmet Clinical Needs in Cardiac Arrhythmia.

Analyst Summary:

Acutus Medical (NASDAQ: AFIB), an arrhythmia management company, reported unaudited financial results for Q4 and full-year 2022. In the fourth quarter of 2022, the company generated $33.4 million in revenue, up from $19.4 million in the same period last year, due to increased demand for its differentiated mapping and therapy platform and geographic expansion. Acutus also reported a gross margin of 75% in Q4 2022 and will continue to focus on improving it in 2023. The company's net loss of $39.1 million for 2022 narrowed from $107.3 million in 2021. 

As stated by the CEO, Vince Burgess, the focus in 2023 will be on growth through geographic expansion and increased adoption of the company's differentiated mapping and therapy platform, and continued improvement in its financial profile.  

Acutus Medical will host a conference call on March 16, 2023, at 4:30 p.m. Eastern Time to discuss the Q4 and full-year 2022 financial results. 

It should be noted that forward-looking statements were made during the report. However, they inherently involve risks and uncertainties that could cause actual results to differ from the forward-looking statements. Therefore, investors should exercise caution when interpreting them.

Acutus Medical (AFIB) sees revenue growth of 12.8% in Q1 2023.

Acutus Medical (AFIB) sees revenue growth of 12.8% in Q1 2023.

$AFIB Reports Strong Q1 2023 Results with Improved Gross Margin, Reduced Operating Expenses, and Increased Revenue

$AFIB Reports Strong Q1 2023 Results with Improved Gross Margin, Reduced Operating Expenses, and Increased Revenue

Announcement: AFIB 8-K Special Filing

Announcement: AFIB 8-K Special Filing

Announcement: AFIB 8-K Special Filing

Announcement: AFIB 8-K Special Filing

Acutus Medical, Inc.: Expanding its Global Reach and Products Portfolio to Address Unmet Clinical Needs in Cardiac Arrhythmia.

Acutus Medical, Inc.: Expanding its Global Reach and Products Portfolio to Address Unmet Clinical Needs in Cardiac Arrhythmia.

$AFIB reports robust Q4 revenue growth and improved financials

$AFIB reports robust Q4 revenue growth and improved financials